[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20010531L - Medisinske aerosolformuleringer - Google Patents

Medisinske aerosolformuleringer

Info

Publication number
NO20010531L
NO20010531L NO20010531A NO20010531A NO20010531L NO 20010531 L NO20010531 L NO 20010531L NO 20010531 A NO20010531 A NO 20010531A NO 20010531 A NO20010531 A NO 20010531A NO 20010531 L NO20010531 L NO 20010531L
Authority
NO
Norway
Prior art keywords
aerosol formulations
moisture
active
compounds
medical aerosol
Prior art date
Application number
NO20010531A
Other languages
English (en)
Other versions
NO328096B1 (no
NO20010531D0 (no
Inventor
Manfred Keller
Kurt Herzog
Rudi Mueller-Walz
Holger Kraus
Original Assignee
Jago Res Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jago Res Ag filed Critical Jago Res Ag
Publication of NO20010531L publication Critical patent/NO20010531L/no
Publication of NO20010531D0 publication Critical patent/NO20010531D0/no
Publication of NO328096B1 publication Critical patent/NO328096B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Anvendelse av faste, farmasøytisk akseptable salter av kromoglysinsyre og/eller nedokromil som bærere i en terapeutisk og profylaktisk ikke-effektiv mengde i suspensjonsaerosolformuleringer av farmasøytisk aktive forbindelser som forbedrer dispergeringsegenskapene, øker den kjemiske og fysiske stabiliteten for fuktighets-sensitive aktive forbindelser, gjør det mulig med en mer nøyaktig dosering, særlig også for forbindelser aktive ved lav dose, og som som regel tillater utelatelsen av overflateaktive midler.
NO20010531A 1998-08-04 2001-01-31 Medisinske aerosolformuleringer samt ny anvendelse av kromoglysinsyre og/eller nedokromil NO328096B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH163398 1998-08-04
PCT/CH1999/000360 WO2000007567A1 (de) 1998-08-04 1999-08-02 Medizinische aerosolformulierungen

Publications (3)

Publication Number Publication Date
NO20010531L true NO20010531L (no) 2001-01-31
NO20010531D0 NO20010531D0 (no) 2001-01-31
NO328096B1 NO328096B1 (no) 2009-12-07

Family

ID=4215022

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20010531A NO328096B1 (no) 1998-08-04 2001-01-31 Medisinske aerosolformuleringer samt ny anvendelse av kromoglysinsyre og/eller nedokromil
NO2012019C NO2012019I2 (no) 1998-08-04 2012-12-10 Kombinasjon av flutikason og formoterol, eller hvilket som helst farmasøytisk akseptabelt salt ellerderivat derav som er beskyttet ved basispatentet, inkludert kombinasjonen av flutikasonpropionat og formoterolfumarat

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2012019C NO2012019I2 (no) 1998-08-04 2012-12-10 Kombinasjon av flutikason og formoterol, eller hvilket som helst farmasøytisk akseptabelt salt ellerderivat derav som er beskyttet ved basispatentet, inkludert kombinasjonen av flutikasonpropionat og formoterolfumarat

Country Status (19)

Country Link
US (1) US6475467B1 (no)
EP (1) EP1102579B1 (no)
JP (1) JP4672143B2 (no)
CN (1) CN1150890C (no)
AT (1) ATE234604T1 (no)
AU (1) AU749697B2 (no)
BE (1) BE2013C027I2 (no)
CA (1) CA2338680C (no)
CY (1) CY2012033I1 (no)
DE (1) DE59904648D1 (no)
DK (1) DK1102579T3 (no)
ES (1) ES2193726T3 (no)
FR (1) FR13C0057I2 (no)
LU (1) LU92254I2 (no)
NO (2) NO328096B1 (no)
NZ (1) NZ509489A (no)
PT (1) PT1102579E (no)
WO (1) WO2000007567A1 (no)
ZA (1) ZA200100569B (no)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
PE20010720A1 (es) * 1999-12-11 2001-07-26 Glaxo Group Ltd Distribuidor de medicamento
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
JP5392880B2 (ja) * 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
EP1326862B1 (de) * 2000-10-12 2004-09-15 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
WO2002036591A2 (de) * 2000-10-31 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative lösungsformulierung mit einem tiotropiumsalz
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
SK286394B6 (sk) * 2001-03-30 2008-09-05 Jagotec Ag Lekárske aerosólové prípravky
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
GEP20063986B (en) * 2002-03-01 2006-12-11 Chiesi Farma Spa Formoterol superfine formulation
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
DE10214264A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen eines Anhydrats
US7311894B2 (en) * 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
US7244415B2 (en) * 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
AU2003240301B2 (en) * 2002-06-25 2008-02-14 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
PL212725B1 (pl) * 2002-12-10 2012-11-30 Sepracor Inc L-winian lewalbuterolu w postaci krystalicznej oraz kompozycja farmaceutyczna zawierajaca L-winian lewalbuterolu
DE60323138D1 (de) * 2002-12-12 2008-10-02 Nycomed Gmbh Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
US20050058606A1 (en) * 2002-12-16 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing HFC solution formulations
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
CN1292748C (zh) * 2003-03-05 2007-01-03 南昌弘益科技有限公司 噻托溴铵吸入粉雾剂及其制备工艺
RS51663B (en) * 2003-03-20 2011-10-31 Boehringer Ingelheim Pharmaceuticals Inc. DOSAGE FORMULATION INHALATOR USING HYDRO-FLUORO-ALKAN AS PROPELLENT
JP2006528228A (ja) * 2003-05-22 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト サルメテロール及びシクレソニドの組合せ物
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
EP1635845A1 (en) 2003-06-13 2006-03-22 ALTANA Pharma AG Formoterol and ciclesonide combination
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
ES2471139T3 (es) * 2003-08-06 2014-06-25 Galephar M/F Combinaciones ventajosas para la inhalaci�n de nacistelina y broncodilatadores
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US8371292B2 (en) * 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
US20070189979A1 (en) * 2003-09-18 2007-08-16 Norton Healthcare Limited T/A Ivax Pharmaceuticals Particles
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
RU2438660C2 (ru) * 2004-02-06 2012-01-10 Меда Фарма Гмбх Унд Ко. Кг Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей
NZ548300A (en) * 2004-02-06 2010-04-30 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD
CN101518532A (zh) * 2004-02-06 2009-09-02 Meda制药有限及两合公司 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20070185067A1 (en) * 2004-02-27 2007-08-09 Altana Pharma Ag Ciclesonide and glycopyrronium combination
JP2007533706A (ja) * 2004-04-20 2007-11-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用
US20050238632A1 (en) * 2004-04-23 2005-10-27 Alburty David S Propellant formulations
AU2013201437B2 (en) * 2004-04-23 2015-09-03 Cydex Pharmaceuticals, Inc DPI formulation containing sulfoalkyl ether cyclodextrin
CA2562585A1 (en) * 2004-04-23 2005-11-10 Cydex, Inc. Dpi formulation containing sulfoalkyl ether cyclodextrin
ITRM20040268A1 (it) * 2004-05-31 2004-08-31 Italchimici S P A Formulazione farmaceutica di una soluzione stabile di formoterolo per via inalatoria e suo precedimento di preparazione.
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
BRPI0512878A (pt) * 2004-07-02 2008-04-15 Boehringer Ingelheim Int formulações de suspensão de aerossol, com tg 227 ea ou tg 134 a como agente propulsor
DE102005029390A1 (de) * 2005-06-23 2007-01-04 Beiersdorf Ag Wirkstoffkombinationen aus Glycopyrroniumbromid und Polyolen
US8343467B2 (en) 2004-12-27 2013-01-01 Beiersdorf Ag Glycopyrrolate in cosmetic preparations
JP3955868B2 (ja) * 2004-12-27 2007-08-08 株式会社キングジム 書類等の綴じ具
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
WO2006097250A1 (en) * 2005-03-16 2006-09-21 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and leukotriene recptor antagonists for the treatment of repiratory diseases
JP2008538758A (ja) * 2005-04-23 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬に加えてベータ受容体刺激薬及びステロイドを含有する吸入用の医薬組成物
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
AU2006243238B2 (en) 2005-05-02 2012-05-24 Boehringer Ingelheim International Gmbh Novel crystalline forms of tiotropium bromide
BRPI0611134A2 (pt) 2005-06-03 2010-08-17 Acrux Dds Pty Ltd método e composição para liberação transdérmica de fármaco
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
AU2012200449B2 (en) * 2005-12-21 2013-07-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
DK1971369T3 (da) 2005-12-21 2009-11-16 Meda Pharma Gmbh & Co Kg Kombination af R,R-glycopyrrolat, rolipram og budesonid til behandling af inflammatoriske sygdomme
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
AU2007333302A1 (en) * 2006-12-07 2008-06-19 Eli Lilly And Company An article comprising prasugrel
DE102007002121B4 (de) * 2007-01-10 2008-12-11 Dräger, Karl-Heinz Verwendung eines Flüssiggasgemisches als nichtbrennbares Treibgas zum Feinstverteilen eines Reiz- oder Kampfstoffes
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
MX350163B (es) 2009-05-29 2017-08-29 Pearl Therapeutics Inc Composiciones para suministro respiratorio de agentes activos y metodos y sistemas asociados.
TR200907237A2 (tr) * 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Tiotropyum kuru toz kombinasyonu
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
TR200907914A2 (tr) * 2009-10-20 2011-05-23 Bi̇lgi̇ç Mahmut Kortlkosteroid içeren kuru toz formunda farmasötik bileşim.
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
RU2561052C2 (ru) * 2009-12-23 2015-08-20 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Комбинированное лечение хронического обструктивного заболевания легких
ES2464520T3 (es) 2009-12-23 2014-06-03 Chiesi Farmaceutici S.P.A. Formulación en aerosol para EPOC
JP5914354B2 (ja) * 2009-12-23 2016-05-11 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Ｃｏｐｄ用併用療法
TR200909790A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum, formoterol ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
TR200909793A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum, mometazon ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
TR200909792A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum, kortikosteroid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
TR200909791A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik bileşim@
TR200909789A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum, budesonid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
EP2721036B1 (en) 2011-06-15 2015-07-22 Takeda GmbH Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds
WO2012171900A1 (en) 2011-06-17 2012-12-20 Nycomed Gmbh Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
ES2619954T3 (es) 2012-12-17 2017-06-27 Parion Sciences, Inc. Derivados de cloropiracinocarboxamida útiles para el tratamiento de enfermedades favorecidas por una hidratación mucosa insuficiente
RU2018138195A (ru) 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
WO2014113638A1 (en) * 2013-01-17 2014-07-24 Aer Devices, Inc. Multi-use albuterol maintenance therapy formulations and devices therefor
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
LT3089735T (lt) 2013-12-30 2018-09-10 Chiesi Farmaceutici S.P.A. Glikopironio bromido ir formoterolio derinio stabili suslėgta aerozolinė tirpalo kompozicija
EP3104853B1 (en) 2014-02-10 2019-10-02 Respivant Sciences GmbH Mast cell stabilizers treatment for systemic disorders
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
BR112018011266B1 (pt) 2015-12-04 2023-11-21 Mexichem Fluor S.A. De C.V. Composição farmacêutica, recipiente vedado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica
WO2018044942A1 (en) 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
CA3037080C (en) 2016-09-19 2021-05-18 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising indacaterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
CA3037092C (en) 2016-09-19 2022-06-21 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising glycopyrrolate and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
CN109715148A (zh) 2016-09-19 2019-05-03 墨西哥氟石股份公司 药物组合物
JP2019531308A (ja) 2016-10-07 2019-10-31 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 肺線維症の治療のためのクロモリン組成物
WO2018069210A1 (en) 2016-10-10 2018-04-19 Takeda Gmbh Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4
BR112019007259A2 (pt) * 2016-10-14 2019-07-02 Glenmark Specialty S.A. recipiente de câmara dupla adequado para uso com um nebulizador e pré-carregado com uma composição nebulizável, kit, composição nebulizável, solução nebulizável aquosa, método para administrar de tiotrópio e formoterol a um paciente com necessidade do mesmo e método para preparar um nebulizador
UA122811C2 (uk) * 2018-08-10 2021-01-06 Наталія Миколаївна Тихонівська Фармацевтична композиція
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
WO2021110239A1 (en) 2019-12-02 2021-06-10 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers
WO2023227781A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227783A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227782A1 (en) * 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (no) 1956-03-21 1900-01-01
BE556587A (no) 1957-01-31 1957-04-11
FI770215A (no) * 1976-01-30 1977-07-31 Fisons Ltd
US4405598A (en) * 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
CA1075854A (en) 1976-08-16 1980-04-22 Charles W. Simons Aerosol propellants for personal products
FR2390951A1 (fr) 1977-05-17 1978-12-15 Oreal Nouvelles compositions cosmetiques sous forme de laques aerosols pour fixer la chevelure
GB2077100B (en) * 1980-04-30 1985-04-24 Fisons Ltd Pharmaceutical compositions containing cromoglycates
JPS61158919A (ja) 1984-12-28 1986-07-18 Taisho Pharmaceut Co Ltd 水虫治療剤
GB8820398D0 (en) * 1988-08-27 1988-09-28 Fisons Plc Pharmaceutical formulation
IE62780B1 (en) * 1988-09-10 1995-02-22 Fisons Plc Inhalation devices with a reduced risk of blockage
DE3839258A1 (de) * 1988-11-21 1990-05-23 Norbert Sass Verfahren zur herstellung eines suspensions-aerosols
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
ATE147973T1 (de) 1990-06-29 1997-02-15 Fisons Plc Druckaerosolzusammensetzung
US5753208A (en) * 1990-11-09 1998-05-19 Egis Gyogyszergyar Antiasthmatic aerosol preparation of sodium cromoglycate
HU205249B (en) * 1990-11-09 1992-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing suspensive aerosole composition
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
ES2216800T3 (es) * 1991-12-18 2004-11-01 Minnesota Mining And Manufacturing Company Formulaciones de aerosol en suspension.
SG42375A1 (en) 1991-12-31 2001-04-17 Solvay Medicinal aerosol formulation
SE523661C2 (sv) 1992-02-05 2004-05-04 American Pacific Corp Gas-vätskeblandning avsedd för användning som brandsläckningsmedel
US5301664A (en) 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
GB9214765D0 (en) 1992-07-11 1992-08-26 Smithkline Beecham Plc Pressurised aerosol formulation
WO1994003056A1 (en) 1992-07-31 1994-02-17 Ian Alexander Edwin Maccormick Aerosol insecticide composition
DE69530325T2 (de) 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
AP791A (en) * 1995-04-14 1999-12-17 Glaxo Wellcome Inc Metered dose inhaler for albuterol.
DE19616573C2 (de) * 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
FR2764899B1 (fr) 1997-06-19 2001-04-06 Boehringer Ingelheim Alimentai Nouveau melange propulseur et les preparations alimentaires en aerosol le contenant

Also Published As

Publication number Publication date
CN1150890C (zh) 2004-05-26
US6475467B1 (en) 2002-11-05
AU749697B2 (en) 2002-07-04
ES2193726T3 (es) 2003-11-01
CA2338680C (en) 2008-10-14
JP4672143B2 (ja) 2011-04-20
WO2000007567A1 (de) 2000-02-17
BE2013C027I2 (no) 2018-12-04
NO328096B1 (no) 2009-12-07
NO2012019I1 (no) 2012-12-27
DK1102579T3 (da) 2003-07-14
CY2012033I2 (el) 2015-08-05
LU92254I2 (fr) 2013-09-17
NO2012019I2 (no) 2014-06-02
EP1102579B1 (de) 2003-03-19
AU4893999A (en) 2000-02-28
NZ509489A (en) 2002-10-25
FR13C0057I2 (fr) 2020-04-03
FR13C0057I1 (no) 2013-11-15
NO20010531D0 (no) 2001-01-31
ZA200100569B (en) 2001-09-26
CY2012033I1 (el) 2015-08-05
CA2338680A1 (en) 2000-02-17
CN1315852A (zh) 2001-10-03
JP2002522374A (ja) 2002-07-23
ATE234604T1 (de) 2003-04-15
EP1102579A1 (de) 2001-05-30
DE59904648D1 (de) 2003-04-24
PT1102579E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
NO20010531L (no) Medisinske aerosolformuleringer
CA2408142A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
HK1036931A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients.
BR9503386A (pt) Formulaçao farmacêutica comprimido dispersivel e processo para a fabricaçao de comprimidos dispersíveis contendo cloridrato de fluoxetina
ES2133785T3 (es) Inhibidores de metaloproteinasas.
BR0014320A (pt) Composições de substâncias terapêuticas solúveis em tocol
PT1027037E (pt) Composicao farmaceutica que compreende clodronato como ingredientes activo e celulose microcristalina silicificada como excipiente
ES2179910T3 (es) Modificacion cristalina del cdch, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
PT96506A (pt) Processo para a preparacao de composicoes orais que incorporam como ingrediente activo pimobendano
MA27702A1 (fr) Preparation de suspensions aqueuses steriles comprenant des ingredients actifs cristallins micronises, destinees a l'inhalation
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
EP1325903A4 (en) DERIVATIVES OF 2,3-DIPHENYLPROPIONIC ACID OR THEIR SALTS, MEDICAMENTS OR INHIBITORS OF CELL ADHESION CONTAINING THE SAME, AND THEIR USE
BRPI0010150B8 (pt) solução oral de prucalopride
ATE348621T1 (de) Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
AU2001285944A1 (en) Fungicidal agent containing n-chlorotaurine and use thereof
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
ATE203903T1 (de) Delta-aminolävulinsäure enthaltendes arzneimittel
WO2005020968A3 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
AU2001258859A1 (en) Pralmorelin-containing nasal drop preparations

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: FLUTIFORM / IFFERA (ALTERNATIVE NAVN FOR SAMME PRODUKT); NAT. REG. NO/DATE: 10-7474-10-7476 20120827; FIRST REG. NO/DATE: 21395-21397 20120710

Spc suppl protection certif: 2012019

Filing date: 20121210

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: FLUTIFORM / IFFERA (ALTERNATIVE NAVN FOR SAMME PRODUKT); NAT. REG. NO/DATE: 10-7474-10-7476 20120827; FIRST REG. NO/DATE: 21395-21397 20120710

Spc suppl protection certif: 2012019

Filing date: 20121210

Extension date: 20240802

MK1K Patent expired